NKGen Biotech reports cognitive improvements in Alzheimer's trial

March 23, 2026 8:05 AM

NKGen Biotech Inc. (OTC: NKGN) announced data from combined Phase 1 trials of its troculeucel therapy showing cognitive improvements in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found